Laura Martínez-Sadurní
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Martínez-Sadurní has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Alba Toll
Maresme Health Consortium
3 shared publications - Daniel Bergé
Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain; Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain
3 shared publications Amira Trabsa
2 shared publications- Anna Mané
Hospital del Mar
2 shared publications A Mané
1 shared publicationAlba Toll
Centro de Investigación Biomédica en Red de Salud Mental. Instituto de Salud Carlos III, Madrid, Spain
1 shared publication
Latest Publications
- 7 October 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 362-373
Differential effect of cannabis use and antipsychotic medication on extracellular free-water in the brain of individuals with early psychosis and controls
Inflammatory changes have been widely reported in psychosis. Cannabis use has been consistently related to increased risk of psychosis, earlier onset, higher rates of relapse and poorer treatment response. However, it is unclear how cannabis use interacts with brain inflammatory changes in psychosis. In this cross-sectional study we used diffusion imaging to measure extracellular free water in the brain (FW), a measure that has been associated with inflammation, in 62 individuals with recent onset psychosis (ROP) and 38 controls, with and without cannabis use. Past cannabis use was associated with lower FW in controls, and conversely, to elevated FW in ROP. This group x past cannabis use interaction was found significant in average GM (p = 0.049), and in cortical regions, including the temporal lobe expanding to parietal regions (TFCE p-FWE < 0.05). Within ROP, antipsychotic exposure was related to lower FW in gray matter and white matter only in the non-cannabis users, with no significant association in cannabis users (p interaction in WM = 0.005, in GM = 0.073). Our results demonstrate a differential effect of cannabis use on FW, a surrogate marker of neuroinflammatory processes and suggest that past cannabis use may influence the effects of antipsychotic medication on the brain. However, given the cross-sectional design and moderate sample size, causal interpretations are limited, and further longitudinal studies are warranted.
- 7 October 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 362-373
Differential effect of cannabis use and antipsychotic medication on extracellular free-water in the brain of individuals with early psychosis and controls
Inflammatory changes have been widely reported in psychosis. Cannabis use has been consistently related to increased risk of psychosis, earlier onset, higher rates of relapse and poorer treatment response. However, it is unclear how cannabis use interacts with brain inflammatory changes in psychosis. In this cross-sectional study we used diffusion imaging to measure extracellular free water in the brain (FW), a measure that has been associated with inflammation, in 62 individuals with recent onset psychosis (ROP) and 38 controls, with and without cannabis use. Past cannabis use was associated with lower FW in controls, and conversely, to elevated FW in ROP. This group x past cannabis use interaction was found significant in average GM (p = 0.049), and in cortical regions, including the temporal lobe expanding to parietal regions (TFCE p-FWE < 0.05). Within ROP, antipsychotic exposure was related to lower FW in gray matter and white matter only in the non-cannabis users, with no significant association in cannabis users (p interaction in WM = 0.005, in GM = 0.073). Our results demonstrate a differential effect of cannabis use on FW, a surrogate marker of neuroinflammatory processes and suggest that past cannabis use may influence the effects of antipsychotic medication on the brain. However, given the cross-sectional design and moderate sample size, causal interpretations are limited, and further longitudinal studies are warranted.
- 9 April 2025
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 39 (3)
Hyperprolactinemia in drug-naïve first episode psychosis and its association with BDNF levels
- 9 April 2025
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 39 (3)
Hyperprolactinemia in drug-naïve first episode psychosis and its association with BDNF levels
- 28 April 2023
- Published by Elsevier in Psychiatry Research
- Vol. 325, 115232
Factors associated with suicide attempts in first-episode psychosis during the first two years after onset
- 28 April 2023
- Published by Elsevier in Psychiatry Research
- Vol. 325, 115232
Factors associated with suicide attempts in first-episode psychosis during the first two years after onset
- 4 April 2019
- Published by Elsevier in Psiquiatría Biológica
- Vol. 26 (2) , 52-55
Síntomas maníacos en encefalitis autoinmune por anticuerpos contra mGluR5: a propósito de un caso
- 4 April 2019
- Published by Elsevier in Psiquiatría Biológica
- Vol. 26 (2) , 52-55
Síntomas maníacos en encefalitis autoinmune por anticuerpos contra mGluR5: a propósito de un caso